Acumen Pharmaceuticals will present three studies at the Alzheimer's Association International Conference 2026, highlighting their Enhanced Brain Delivery (EBD) technology and early Alzheimer's disease research. Their collaboration with JCR Pharmaceuticals aims to improve brain delivery of therapies targeting toxic amyloid beta oligomers, a key factor in Alzheimer's. They are also conducting a Phase 2 trial (ALTITUDE-AD) of their drug sabirnetug (ACU193) for early Alzheimer's, with topline results expected late 2026. These presentations reflect progress in developing more effective treatments for Alzheimer's disease.
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
